Volastra
Timothy Bowler currently serves as the VP of Clinical Development at Volastra Therapeutics since November 2023. Prior to this role, Timothy held several positions at Pfizer from June 2021 to November 2023, including Global Clinical Lead and Senior Director, as well as Global Clinical Lead in Oncology. Timothy's experience also includes serving as Medical Director and Associate Medical Director at Regeneron from July 2018 to June 2021 and as MD PhD at Memorial Sloan Kettering Cancer Center from July 2015 to July 2018. Timothy earned a Bachelor of Arts in Genetics from the University of Cambridge between 1994 and 1997.
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.